Updated Jul 16, 2026
Waheed Nadia has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $221K.

Nadia Waheed is the Chief Medical Officer at Ocular Therapeutix, Inc., a biotechnology company focused on developing therapies for eye diseases. She has experience in the pharmaceutical industry, particularly in ophthalmology.
| Role | Chief Medical Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | OCUL | OCULAR THERAPEUTIX, INC | S — Open-market sale | 14.8K | $8.27 | $123K |
| 2026-02-24 | OCUL | OCULAR THERAPEUTIX, INC | S — Open-market sale | 3.5K | $7.74 | $27K |
| 2026-02-18 | OCUL | OCULAR THERAPEUTIX, INC | S — Open-market sale | 7.9K | $9.04 | $71K |
| 2025-08-12 | OCUL | OCULAR THERAPEUTIX, INC | A — Grant or award | 40.4K | $0.00 |
Nadia Waheed is the Chief Medical Officer at Ocular Therapeutix, Inc., a biotechnology company focused on developing therapies for eye diseases. She has experience in the pharmaceutical industry, particularly in ophthalmology.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($221K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Waheed Nadia profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.